
Cumberland Pharmaceuticals CPIX
€ 6.57
0.27%
Land |
|
IPO-Jahr |
2009 |
Branche |
Arzneimittelhersteller |
Börse |
NASDAQ GLOBAL |
Anteile |
14.9 M |
Marktkapitalisierung |
$ 110 M |
EBITDA (LTM) |
$ 2.77 M |
P/E (LTM) |
-75.444444 |
P/S (LTM) |
7.373743 |
EPS (LTM) |
-0.09 |
Andere Aktien der Branche "Arzneimittelhersteller"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
|
Bausch Health Companies
BHC
|
$ 5.8 | 1.22 % | $ 2.15 B | NYSE | ||
|
Canopy Growth Corporation
CGC
|
$ 0.88 | 0.53 % | $ 262 M | Nasdaq Global Select Market | ||
|
China Pharma Holdings
CPHI
|
$ 0.66 | 0.61 % | $ 2.83 M | NYSE American | ||
|
Cronos Group
CRON
|
$ 3.23 | 0.47 % | $ 1.24 B | Nasdaq Global Market | ||
|
Emergent BioSolutions
EBS
|
$ 6.33 | 0.87 % | $ 339 M | NYSE,SPB | ||
|
Evolus
EOLS
|
$ 7.14 | 0.13 % | $ 460 M | Nasdaq Global Market | ||
|
Harrow Health
HROW
|
$ 30.48 | 0.16 % | $ 1.12 B | Nasdaq Global Market | ||
|
OrganiGram Holdings
OGI
|
$ 0.95 | 0.91 % | $ 90.5 M | Nasdaq Global Select Market | ||
|
Organogenesis Holdings
ORGO
|
$ 1.33 | 2.19 % | $ 169 M | Nasdaq Capital Market | ||
|
Pacira BioSciences
PCRX
|
$ 25.21 | 0.8 % | $ 1.12 B | Nasdaq Global Select Market,SPB | ||
|
Perrigo Company plc
PRGO
|
$ 14.26 | 1.71 % | $ 1.98 B | NYSE | ||
|
Relmada Therapeutics
RLMD
|
$ 3.62 | 0.68 % | $ 143 M | Nasdaq Global Select Market,SPB | ||
|
Rockwell Medical
RMTI
|
$ 8.65 | 0.93 % | $ 311 M | Nasdaq Global Market | ||
|
SCYNEXIS
SCYX
|
$ 5.12 | 0.37 % | $ 256 M | Nasdaq Global Select Market | ||
|
Solid Biosciences
SLDB
|
$ 6.85 | 0.43 % | $ 599 M | Nasdaq Global Select Market,SPB | ||
|
Sundial Growers
SNDL
|
$ 1.24 | 0.4 % | $ 320 M | Nasdaq Global Select Market | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 1.23 | 0.4 % | $ 2.07 M | Nasdaq Capital Market | ||
|
Tilray
TLRY
|
$ 3.61 | 1.12 % | $ 3.21 B | Nasdaq Global Select Market | ||
|
TherapeuticsMD
TXMD
|
$ 2.05 | 0.99 % | $ 23.7 M | Nasdaq Global Select Market | ||
|
Veru
VERU
|
$ 2.51 | 3.91 % | $ 36.8 M | Nasdaq Capital Market | ||
|
Viatris
VTRS
|
$ 17.6 | 0.8 % | $ 20.2 B | Nasdaq Global Select Market,SPB | ||
|
cbdMD
YCBD
|
$ 0.46 | 1.22 % | $ 1.85 M | NYSE American | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | NYSE | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | Nasdaq Global Select Market | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | Nasdaq Global Market | ||
|
Assertio Holdings
ASRT
|
- | - | $ 150 M | Nasdaq Capital Market | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | Nasdaq Global Select Market | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Nasdaq Global Select Market | ||
|
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | Nasdaq Capital Market | ||
|
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | NYSE American | ||
|
Avadel Pharmaceuticals plc
AVDL
|
- | - | $ 2.06 B | Nasdaq Global Select Market | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | Nasdaq Capital Market | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | NYSE | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | NYSE,SPB | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | Nasdaq Capital Market | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | Nasdaq Global Market,SPB | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | Nasdaq Global Select Market | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | Nasdaq Global Select Market,SPB | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | Nasdaq Global Select Market,SPB | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | Nasdaq Global Market | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | Nasdaq Global Select Market | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | Nasdaq Capital Market | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | Nasdaq Capital Market | ||
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | Nasdaq Global Market | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | Nasdaq Capital Market | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | Nasdaq Global Select Market | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | Nasdaq Global Market,SPB | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | Nasdaq Global Select Market,SPB | ||
|
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | Nasdaq Global Market,SPB |